Peptide comparisons

59 pairs people often look up together, side by side: FDA status, the HHS and FDA compounding lists, the kinds of studies each profile cites, and recent official events.

Every row comes from the two published profiles and keeps their citations. A comparison is not a ranking or a recommendation. For a single peptide, see all peptides or the status tracker; for lists, see common questions.

Metabolic and weight

ComparisonFirstSecond
Semaglutide vs TirzepatideFDA-approvedFDA-approved as Ozempic, Rybelsus and Wegovy↗↗↗↗FDA-approvedFDA-approved as Mounjaro and Zepbound↗↗↗
Tirzepatide vs RetatrutideFDA-approvedFDA-approved as Mounjaro and Zepbound↗↗↗In clinical trialsIn clinical trials; not FDA-approved↗↗↗
Semaglutide vs RetatrutideFDA-approvedFDA-approved as Ozempic, Rybelsus and Wegovy↗↗↗↗In clinical trialsIn clinical trials; not FDA-approved↗↗↗
Liraglutide vs SemaglutideFDA-approvedFDA-approved as Victoza, Saxenda and generic versions↗↗↗↗FDA-approvedFDA-approved as Ozempic, Rybelsus and Wegovy↗↗↗↗
Liraglutide vs TirzepatideFDA-approvedFDA-approved as Victoza, Saxenda and generic versions↗↗↗↗FDA-approvedFDA-approved as Mounjaro and Zepbound↗↗↗
Dulaglutide vs SemaglutideFDA-approvedFDA-approved as Trulicity↗↗FDA-approvedFDA-approved as Ozempic, Rybelsus and Wegovy↗↗↗↗
Dulaglutide vs TirzepatideFDA-approvedFDA-approved as Trulicity↗↗FDA-approvedFDA-approved as Mounjaro and Zepbound↗↗↗
Exenatide vs LiraglutideFDA-approvedFDA-approved as Byetta, Bydureon and generic exenatide↗↗↗↗↗FDA-approvedFDA-approved as Victoza, Saxenda and generic versions↗↗↗↗
Cagrilintide vs SemaglutideIn clinical trialsIn clinical trials; not FDA-approved↗↗↗FDA-approvedFDA-approved as Ozempic, Rybelsus and Wegovy↗↗↗↗
Survodutide vs RetatrutideIn clinical trialsIn clinical trials; not FDA-approved↗↗↗In clinical trialsIn clinical trials; not FDA-approved↗↗↗
Survodutide vs TirzepatideIn clinical trialsIn clinical trials; not FDA-approved↗↗↗FDA-approvedFDA-approved as Mounjaro and Zepbound↗↗↗
Mazdutide vs TirzepatideApproval reported abroadChina: approval reported by local government sources↗↗FDA-approvedFDA-approved as Mounjaro and Zepbound↗↗↗
Maridebart cafraglutide vs TirzepatideIn clinical trialsIn clinical trials; not FDA-approved↗↗↗FDA-approvedFDA-approved as Mounjaro and Zepbound↗↗↗
Amycretin vs SemaglutideIn clinical trialsIn clinical trials; not FDA-approved↗↗FDA-approvedFDA-approved as Ozempic, Rybelsus and Wegovy↗↗↗↗
Pramlintide vs CagrilintideFDA-approvedFDA-approved as Symlin↗↗In clinical trialsIn clinical trials; not FDA-approved↗↗↗
Petrelintide vs CagrilintideIn clinical trialsIn clinical trials; not FDA-approved↗↗↗In clinical trialsIn clinical trials; not FDA-approved↗↗↗
AOD-9604 vs SemaglutideNot FDA-approvedNot FDA-approved; FDA advised against adding it to the compounding list↗↗↗FDA-approvedFDA-approved as Ozempic, Rybelsus and Wegovy↗↗↗↗
AOD-9604 vs TesamorelinNot FDA-approvedNot FDA-approved; FDA advised against adding it to the compounding list↗↗↗FDA-approvedFDA-approved as Egrifta for HIV-associated abdominal fat↗↗
Glucagon vs DasiglucagonFDA-approvedFDA-approved as Gvoke, Baqsimi and other glucagon products↗↗↗↗FDA-approvedFDA-approved as Zegalogue for severe low blood sugar; discontinued↗↗
Orforglipron vs SemaglutideFDA-approvedFDA-approved as Foundayo for weight reduction in adults↗↗FDA-approvedFDA-approved as Ozempic, Rybelsus and Wegovy↗↗↗↗
Orforglipron vs TirzepatideFDA-approvedFDA-approved as Foundayo for weight reduction in adults↗↗FDA-approvedFDA-approved as Mounjaro and Zepbound↗↗↗
Efpeglenatide vs SemaglutideIn clinical trialsIn clinical trials; not FDA-approved↗↗↗FDA-approvedFDA-approved as Ozempic, Rybelsus and Wegovy↗↗↗↗
Albiglutide vs DulaglutideFDA-approvedFDA-approved as Tanzeum; discontinued↗FDA-approvedFDA-approved as Trulicity↗↗
VK2735 vs TirzepatideIn clinical trialsIn clinical trials; not FDA-approved↗↗↗FDA-approvedFDA-approved as Mounjaro and Zepbound↗↗↗

Liver

ComparisonFirstSecond
Efinopegdutide vs SurvodutideNot FDA-approvedNo FDA approval reported; studied in clinical trials↗↗In clinical trialsIn clinical trials; not FDA-approved↗↗↗

Hormones

ComparisonFirstSecond
CJC-1295 vs IpamorelinNot FDA-approvedUnapproved new drug in cited enforcement record↗Not FDA-approvedUnapproved new drug in cited enforcement record↗
Sermorelin vs TesamorelinNot FDA-approvedFDA approval withdrawn in 2009 at the maker’s request, not for safety or effectiveness↗↗FDA-approvedFDA-approved as Egrifta for HIV-associated abdominal fat↗↗
Ipamorelin vs SermorelinNot FDA-approvedUnapproved new drug in cited enforcement record↗Not FDA-approvedFDA approval withdrawn in 2009 at the maker’s request, not for safety or effectiveness↗↗
CJC-1295 vs SermorelinNot FDA-approvedUnapproved new drug in cited enforcement record↗Not FDA-approvedFDA approval withdrawn in 2009 at the maker’s request, not for safety or effectiveness↗↗
CJC-1295 vs TesamorelinNot FDA-approvedUnapproved new drug in cited enforcement record↗FDA-approvedFDA-approved as Egrifta for HIV-associated abdominal fat↗↗
Ipamorelin vs TesamorelinNot FDA-approvedUnapproved new drug in cited enforcement record↗FDA-approvedFDA-approved as Egrifta for HIV-associated abdominal fat↗↗
GHRP-2 vs GHRP-6Not FDA-approvedNo FDA approval reported; on FDA’s compounding safety-risk list (category 2)↗Not FDA-approvedNo FDA approval reported; on FDA’s compounding safety-risk list (category 2)↗
GHRP-2 vs IpamorelinNot FDA-approvedNo FDA approval reported; on FDA’s compounding safety-risk list (category 2)↗Not FDA-approvedUnapproved new drug in cited enforcement record↗
GHRP-6 vs IpamorelinNot FDA-approvedNo FDA approval reported; on FDA’s compounding safety-risk list (category 2)↗Not FDA-approvedUnapproved new drug in cited enforcement record↗
GHRP-6 vs HexarelinNot FDA-approvedNo FDA approval reported; on FDA’s compounding safety-risk list (category 2)↗Not FDA-approvedNo FDA approval reported↗↗
Octreotide vs LanreotideFDA-approvedFDA-approved as Sandostatin and other octreotide products↗↗↗↗↗FDA-approvedFDA-approved as Somatuline Depot and other lanreotide products↗↗↗↗
Oxytocin vs VasopressinFDA-approvedFDA-approved as Pitocin for labor and bleeding after birth↗↗FDA-approvedFDA-approved as Vasostrict for vasodilatory shock↗↗
Desmopressin vs VasopressinFDA-approvedFDA-approved as DDAVP for diabetes insipidus and bedwetting↗↗FDA-approvedFDA-approved as Vasostrict for vasodilatory shock↗↗
MK-677 vs IpamorelinNot FDA-approvedNo FDA approval reported; on FDA’s compounding safety-risk list (category 2)↗↗Not FDA-approvedUnapproved new drug in cited enforcement record↗
MK-677 vs SermorelinNot FDA-approvedNo FDA approval reported; on FDA’s compounding safety-risk list (category 2)↗↗Not FDA-approvedFDA approval withdrawn in 2009 at the maker’s request, not for safety or effectiveness↗↗
MK-677 vs TesamorelinNot FDA-approvedNo FDA approval reported; on FDA’s compounding safety-risk list (category 2)↗↗FDA-approvedFDA-approved as Egrifta for HIV-associated abdominal fat↗↗

Bone and growth

ComparisonFirstSecond
Teriparatide vs AbaloparatideFDA-approvedFDA-approved as Forteo and other teriparatide products↗↗↗↗↗↗FDA-approvedFDA-approved as Tymlos for osteoporosis↗↗
Mecasermin vs IGF-1 LR3FDA-approvedFDA-approved as Increlex for severe primary IGF-1 deficiency in children↗↗Not FDA-approvedNo FDA approval reported; studied only in cells and animals↗↗

Gut and digestion

ComparisonFirstSecond
BPC-157 vs TB-500Not FDA-approvedNot an FDA-approved drug↗Not FDA-approvedNot an FDA-approved drug↗
BPC-157 vs KPVNot FDA-approvedNot an FDA-approved drug↗Not FDA-approvedNot an FDA-approved drug↗
BPC-157 vs GHK-CuNot FDA-approvedNot an FDA-approved drug↗Not FDA-approvedFDA compounding-list review for non-injectable routes↗
Linaclotide vs PlecanatideFDA-approvedFDA-approved as Linzess↗↗FDA-approvedFDA-approved as Trulance↗↗
Teduglutide vs GlepaglutideFDA-approvedFDA-approved as Gattex for short bowel syndrome↗↗In clinical trialsIn clinical trials; not FDA-approved↗↗

Brain, nerves and sleep

ComparisonFirstSecond
Epitalon vs MOTS-cNot FDA-approvedNot an FDA-approved drug↗Not FDA-approvedNot an FDA-approved drug↗
Semax vs SelankNot FDA-approvedNot an FDA-approved drug↗Not FDA-approvedNo FDA approval reported; FDA lists safety concerns from a withdrawn compounding nomination↗

Skin

ComparisonFirstSecond
Melanotan II vs BremelanotideNot FDA-approvedNo FDA approval reported; on FDA’s compounding safety-risk list↗FDA-approvedFDA-approved as Vyleesi for HSDD in premenopausal women↗↗
Melanotan II vs AfamelanotideNot FDA-approvedNo FDA approval reported; on FDA’s compounding safety-risk list↗FDA-approvedFDA-approved as Scenesse for erythropoietic protoporphyria↗↗

Sexual and reproductive health

ComparisonFirstSecond
Cetrorelix vs GanirelixFDA-approvedFDA-approved as Cetrotide for use in controlled ovarian stimulation↗↗FDA-approvedFDA-approved as ganirelix acetate for use in controlled ovarian hyperstimulation↗↗
Gonadorelin vs LeuprolideFDA-approvedFDA-approved as Factrel and Lutrepulse; discontinued↗↗FDA-approvedFDA-approved as Lupron, Eligard, Vobrig and other leuprolide products↗↗↗↗↗↗

Tissue repair and wound healing

ComparisonFirstSecond
TB-500 vs Thymosin beta-4Not FDA-approvedNot an FDA-approved drug↗Not FDA-approvedNo FDA approval reported↗↗

Inflammation and immune

ComparisonFirstSecond
Thymosin alpha-1 vs Thymosin beta-4Not FDA-approvedNot FDA-approved; FDA advised against adding it to the compounding list↗↗↗Not FDA-approvedNo FDA approval reported↗↗

Cancer

ComparisonFirstSecond
Leuprolide vs TriptorelinFDA-approvedFDA-approved as Lupron, Eligard, Vobrig and other leuprolide products↗↗↗↗↗↗FDA-approvedFDA-approved as Trelstar for advanced prostate cancer↗↗
Goserelin vs LeuprolideFDA-approvedFDA-approved as Zoladex for prostate cancer, breast cancer and endometriosis↗↗FDA-approvedFDA-approved as Lupron, Eligard, Vobrig and other leuprolide products↗↗↗↗↗↗
Degarelix vs LeuprolideFDA-approvedFDA-approved as Firmagon for advanced prostate cancer↗↗FDA-approvedFDA-approved as Lupron, Eligard, Vobrig and other leuprolide products↗↗↗↗↗↗